Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
China
Pharma
Ono-Deciphera, Novartis-PeptiDream, WuXi Bio—Fierce Pharma Asia
Ono will buy Deciphera for $2.4 billion. Novartis invests further in radiotherapy with two deals. WuXi Biologics has withdrawn from the BIO 2024.
Angus Liu
May 3, 2024 7:20am
WuXi Bio pulls out of 2024 BIO convention
May 1, 2024 2:48pm
BIO survey to elucidate US biopharma's reliance on Chinese CDMOs
May 1, 2024 11:00am
WuXi AppTec stays the course amid US biosecurity crackdown
Apr 30, 2024 9:30am
Novartis, Neurocrine-Takeda, Enhertu—Fierce Pharma Asia
Apr 26, 2024 5:45am
Novartis reviews ties to China amid US biosecurity crackdown
Apr 23, 2024 11:07am